(This is the third blank-check company, or SPAC, sponsored by an affiliate of Eli Casdin, founder and chief investment officer of Casdin Capital, and Keith Meister, founder and chief investment officer of Corvex Management, two leading investment firms. Mr. Casdin is the CEO of CM Life Sciences III, Inc., and Mr. Meister is the chairman.)

We intend to focus our efforts on the life sciences sector. CM Life Sciences III was founded to take advantage of a dynamic life sciences sector that continues to be buoyed by innovation. With a broadening set of applications for biotechnology that includes research tools and infrastructure, diagnostics, therapeutics, data, and industrial outputs, the life sciences sector offers compelling opportunities for investors who possess a broad overview and understand the trends and themes. CM Life Sciences III is that type of investment partnership, combining the unique industry experience, operational expertise and investment savvy of Mr. Casdin and Mr. Meister to bring together strong companies and management teams and work with them to capitalize on opportunities.

(Note: CM Life Sciences III upsized its SPAC IPO at pricing on April 6, 2021: 48 million units, up from 40 million, were priced at $10 each to raise $480 million.)